An expanded access record providing Tucatinib, sponsored by Seagen Inc.. No longer available. Per ClinicalTrials.gov, last updated 2020-02-25.
Sponsored by Seagen Inc. (part of Pfizer) · Expanded access
Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is one of 3 of another kind, and was the 102nd registered.
14,829 studies on the registry are indexed under Breast Neoplasms; 3,318 are open to participants now.
Browse Breast Neoplasms studies →6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, China and 5 more countries
Ages 18+
Pfizer
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
Of the 2,398 Breast Neoplasms studies recruiting now, 1,569 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 56 · Phase 3 25 · Phase 4 3
First in 1998; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 75 across the 121 interventional studies, 399 across the 56 observational. Of the 145 that completed or were terminated, 94 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
8 of the studies in Breast Neoplasms by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT06495164PfizerA Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer | 2026-12-30 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT05382364PfizerSafety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 182 studies in Breast Neoplasms by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information (medinfo@seagen.com).
Inclusion Criteria:
-
Exclusion Criteria:
-
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.